Genetics Flashcards
Role of HRT in BRCA-1 pts s/p RR BSO (872 pts-mean age 43yo, f/u 7.6y)
after 10y cumulative incidence of breast cancer was 12% in E only vs. 22% among EP HRT
No association w/ breast ca in RR BSO>45yo
/\ Year of HRT use among <45yo RR BSO, effect on breast cancer incidence:
E: \ by 18%
EP: / by 14% but not ss
UK pts with >10% risk of ovarian cancer: attitudes towards RRESDO (risk reducing early salpingectomy and delayed oophorectomy) vs RRSO?
69% considered acceptable to participate in research regarding RRESDO
> likely acceptable among women concerned about sexual dysfunction (OR 2.9) or had dysfunction p menopause (5.3)
RRSO satisfaction (N-160) among pre-M and post-M:
yes: 89 vs 95%
regret: 9 vs 1%
Mutations among high grade serous ovarian cancer patients: PARPrev 2020
BRCA: 14-18%
somatic BRCA or inactivation due to methylation: 3%
Overall HRD (homologous recombination deficiency) in up to 50%
Solo1: RCT of 2 years of olaparib 300mg bid in BRCA+, advanced stage, serous and endometrioid OvCa, after PR or CR to initial platinum based CT: post-hoc PFS analysis after 5 years of f/u?
Median PFS of:
56 vs. 14 months
